Choosing the right regimen for patients with nAMD

My guest for this special episode is Prof. Jean- François Korobelnik from the Department of Ophthalmology at the University Hospital, and at CHU Bordeaux, in Bordeaux, France. In this episode, Jean-François and I explore the importance of choosing the right regimen for our patients with nAMD. We discuss the evidence we can gather from clinical trials, and the lessons we learn from patients we see during clinical practice. We also explore the algorithm developed by the Vision Academy to choose the best regimen for patients.To learn more about how to choose the best treatment regimens to optimize outcomes for patients with nAMD, read the Vision Academy Viewpoint, and the accompanying slide deck. Please also visit the Vision Academy website. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures:Professor Anat LoewensteinConsultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant.Professor Jean- François KorobelnikConsultant: Abbvie, Adverum, Apellis, Bayer, Boehringer-Ingelheim, Carl Zeiss Meditec, Eyepoint Pharma, Ocular Therapeutix, Roche, SeaBeLife, Thea; member of the data safety monitoring board or advisory board for Alexion, Novo Nordisk, and Opthea.April 2025 | PP-PF-OPHT-ALL-0215-1Further information on topics discussed in this podcast:Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye (Lond). 2024. doi: 10.1038/s41433-024-03370-0. Gemenetzi M, Patel PJ. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmol Ther. 2017;6:79-92. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212-9.This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.